{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:47:04Z","timestamp":1791416824312,"version":"4.3.3"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most patients with ovarian cancer are diagnosed late in progression and often experience tumor recurrence and relapses due to drug resistance. Surface expression of matrix metalloprotease (MMP)-14 on ovarian cancer cells stimulates a tumor\u2013stromal signaling pathway that promotes angiogenesis and tumor growth. In a cohort of 92 patients, we found that MMP-14 was increased in the serum of women with malignant ovarian tumors. Therefore, we investigated the preclinical efficacy of a MMP-14 monoclonal antibody that could inhibit the migratory and invasive properties of aggressive ovarian cancer cells in vitro. MMP-14 antibody disrupted ovarian tumor\u2013stromal communication and was equivalent to Avastin in suppressing blood vessel growth in mice harboring Matrigel plugs. These effects on angiogenesis correlated with downregulation of several important angiogenic factors. Furthermore, mice with ovarian cancer tumors treated with anti\u2013MMP-14 monotherapy showed a marked and sustained regression in tumor growth with decreased angiogenesis compared with immunoglobulin G (IgG)-treated controls. In a model of advanced peritoneal ovarian cancer, MMP-14\u2013dependent invasion and metastasis was effectively inhibited by intraperitoneal administration of monoclonal MMP-14 antibody. Together, these studies provide a preclinical proof-of-concept for MMP-14 targeting as an adjuvant treatment strategy for advanced ovarian cancer. Cancer Res; 73(8); 2457\u201367. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-12-1426","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T22:35:14Z","timestamp":1361313314000},"page":"2457-2467","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Selective Blockade of Matrix Metalloprotease-14 with a Monoclonal Antibody Abrogates Invasion, Angiogenesis, and Tumor Growth in Ovarian Cancer"],"prefix":"10.1158","volume":"73","author":[{"given":"Rajani","family":"Kaimal","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raid","family":"Aljumaily","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Tressel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutika V.","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Covic","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Kuliopulos","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Zarwan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young B.","family":"Kim","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Sharifi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"},{"name":"Authors' Affiliations:\u20081Molecular Oncology Research Institute; Departments of 2Medicine, 3Obstetrics and Gynecology, and 4Pathology, Tufts Medical Center; 5Departments of Biochemistry and Genetics, Tufts University Medical School, Boston; 6Department of Hematology and Oncology, Lahey Clinic Medical Center, Burlington; and 7Mt Auburn Hospital, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,4,15]]},"reference":[{"key":"2022061704055827400_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"2022061704055827400_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1535-6108(04)00002-9","article-title":"Focus on epithelial ovarian cancer","volume":"5","author":"Ozols","year":"2004","journal-title":"Cancer Cell"},{"key":"2022061704055827400_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061704055827400_bib4","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/1535-7163.MCT-08-0177","article-title":"Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer","volume":"7","author":"Agarwal","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2022061704055827400_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1172\/JCI117933","article-title":"The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer","volume":"95","author":"Negus","year":"1995","journal-title":"J Clin Invest"},{"key":"2022061704055827400_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/djn024","article-title":"Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth","volume":"100","author":"Merritt","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"2022061704055827400_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/0008-5472.CAN-11-2178","article-title":"A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment","volume":"72","author":"Kulbe","year":"2012","journal-title":"Cancer Res"},{"key":"2022061704055827400_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"2022061704055827400_bib9","doi-asserted-by":"crossref","first-page":"10849","DOI":"10.1158\/0008-5472.CAN-07-1791","article-title":"RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis","volume":"67","author":"Blackburn","year":"2007","journal-title":"Cancer Res"},{"key":"2022061704055827400_bib10","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","article-title":"Experience with bevacizumab in the management of epithelial ovarian cancer","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022061704055827400_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2011.38.8413","article-title":"Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer","volume":"30","author":"Sood","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022061704055827400_bib12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"2022061704055827400_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4615-0081-0_9","article-title":"Matrix metalloproteinases and tumor progression","volume":"532","author":"Freije","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"2022061704055827400_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"2022061704055827400_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ygyno.2011.07.034","article-title":"Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels","volume":"123","author":"Coticchia","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2022061704055827400_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cell.2004.12.018","article-title":"PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells","volume":"120","author":"Boire","year":"2005","journal-title":"Cell"},{"key":"2022061704055827400_bib17","first-page":"5224","article-title":"Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation","volume":"63","author":"Belotti","year":"2003","journal-title":"Cancer Res"},{"key":"2022061704055827400_bib18","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1074\/jbc.M608428200","article-title":"Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression","volume":"282","author":"Barbolina","year":"2007","journal-title":"J Biol Chem"},{"key":"2022061704055827400_bib19","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1158\/1078-0432.CCR-05-2338","article-title":"The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer","volume":"12","author":"Kamat","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061704055827400_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/370061a0","article-title":"A matrix metalloproteinase expressed on the surface of invasive tumour cells","volume":"370","author":"Sato","year":"1994","journal-title":"Nature"},{"key":"2022061704055827400_bib21","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.onc.1208305","article-title":"Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma","volume":"24","author":"Petrella","year":"2005","journal-title":"Oncogene"},{"key":"2022061704055827400_bib22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"key":"2022061704055827400_bib23","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/0008-5472.CAN-08-4151","article-title":"Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination","volume":"69","author":"Moss","year":"2009","journal-title":"Cancer Res"},{"key":"2022061704055827400_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0092-8674(03)00513-0","article-title":"Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix","volume":"114","author":"Hotary","year":"2003","journal-title":"Cell"},{"key":"2022061704055827400_bib25","doi-asserted-by":"crossref","first-page":"51148","DOI":"10.1074\/jbc.M409074200","article-title":"The hemopexin domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) Is not required for its activation of proMMP2 on cell surface but is essential for MT1-MMP-mediated invasion in three-dimensional type I collagen","volume":"279","author":"Wang","year":"2004","journal-title":"J Biol Chem"},{"key":"2022061704055827400_bib26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1172\/JCI33775","article-title":"The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin","volume":"118","author":"Kenny","year":"2008","journal-title":"J Clin Invest"},{"key":"2022061704055827400_bib27","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1158\/0008-5472.CAN-09-4341","article-title":"Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy","volume":"70","author":"Agarwal","year":"2010","journal-title":"Cancer Res"},{"key":"2022061704055827400_bib28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-08-3255","article-title":"Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis","volume":"69","author":"Devy","year":"2009","journal-title":"Cancer Res"},{"key":"2022061704055827400_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc1821","article-title":"Tumour microenvironment\u2014opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy","volume":"6","author":"Overall","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2022061704055827400_bib30","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2009.23.5556","article-title":"Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer","volume":"27","author":"Roy","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022061704055827400_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1749-6632.1999.tb07688.x","article-title":"Preclinical and clinical studies of MMP inhibitors in cancer","volume":"878","author":"Drummond","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"2022061704055827400_bib32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1126\/science.1067100","article-title":"Matrix metalloproteinase inhibitors and cancer: trials and tribulations","volume":"295","author":"Coussens","year":"2002","journal-title":"Science"},{"key":"2022061704055827400_bib33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.284.5415.808","article-title":"Effects of angiogenesis inhibitors on multistage carcinogenesis in mice","volume":"284","author":"Bergers","year":"1999","journal-title":"Science"},{"key":"2022061704055827400_bib34","doi-asserted-by":"crossref","first-page":"12080","DOI":"10.1074\/jbc.275.16.12080","article-title":"Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation","volume":"275","author":"Hernandez-Barrantes","year":"2000","journal-title":"J Biol Chem"},{"key":"2022061704055827400_bib35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.153.5.893","article-title":"Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration","volume":"153","author":"Kajita","year":"2001","journal-title":"J Cell Biol"},{"key":"2022061704055827400_bib36","doi-asserted-by":"crossref","first-page":"8716","DOI":"10.1038\/sj.onc.1206962","article-title":"Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors","volume":"22","author":"Ueda","year":"2003","journal-title":"Oncogene"},{"key":"2022061704055827400_bib37","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/0008-5472.CAN-09-3515","article-title":"Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression","volume":"70","author":"Littlepage","year":"2010","journal-title":"Cancer Res"},{"key":"2022061704055827400_bib38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.2005.03.170","article-title":"Phase III study of matrix metalloproteinase inhibitor prinomastat in non\u2013small-cell lung cancer","volume":"23","author":"Bissett","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061704055827400_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem J"},{"key":"2022061704055827400_bib40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ng1249","article-title":"Loss of collagenase-2 confers increased skin tumor susceptibility to male mice","volume":"35","author":"Balb\u00edn","year":"2003","journal-title":"Nat Genet"},{"key":"2022061704055827400_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1385\/MB:25:3:241","article-title":"Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases","volume":"25","author":"Maskos","year":"2003","journal-title":"Mol Biotechnol"},{"key":"2022061704055827400_bib42","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ceb.2005.08.015","article-title":"Cell migration in 3D matrix","volume":"17","author":"Even-Ram","year":"2005","journal-title":"Curr Opin Cell Biol"},{"key":"2022061704055827400_bib43","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1083\/jcb.200405001","article-title":"MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix","volume":"167","author":"Chun","year":"2004","journal-title":"J Cell Biol"},{"key":"2022061704055827400_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0092-8674(00)80064-1","article-title":"MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover","volume":"99","author":"Holmbeck","year":"1999","journal-title":"Cell"},{"key":"2022061704055827400_bib45","doi-asserted-by":"crossref","first-page":"13564","DOI":"10.1074\/jbc.M307688200","article-title":"Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases","volume":"279","author":"Sounni","year":"2004","journal-title":"J Biol Chem"},{"key":"2022061704055827400_bib46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat Cell Biol"},{"key":"2022061704055827400_bib47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0006-291X(03)01405-0","article-title":"Pro-MMP-9 activation by the MT1-MMP\/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes","volume":"308","author":"Toth","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2022061704055827400_bib48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ncponc1051","article-title":"Angiogenesis as a strategic target for ovarian cancer therapy","volume":"5","author":"Spannuth","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"2022061704055827400_bib49","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/hq0701.093685","article-title":"Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis","volume":"21","author":"Pepper","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022061704055827400_bib50","first-page":"6624","article-title":"Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2","volume":"61","author":"Kunkel","year":"2001","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/8\/2457\/2695001\/2457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/8\/2457\/2695001\/2457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:17:14Z","timestamp":1655461034000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/73\/8\/2457\/586922\/Selective-Blockade-of-Matrix-Metalloprotease-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,15]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,4,15]]},"published-print":{"date-parts":[[2013,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-12-1426","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22398899.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398887.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398887","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398896","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398893","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6505178","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398896.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398890.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398890","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22398893.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6505178.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,15]]}}}